[Trends in development of new antifungal agents in Japan].
After year of 2001, we have had some new antifungal agents, such as micafungin, voriconazole and ambisome in Japan. However, some deep-seated fungal infections are still difficult to control. For example, successful outcome in the treatment of pulmonary aspergillosis are around 40-50%. Moreover, new problems, such as resistant issues, break-through infections and economical problems have been happened. Some new antifungals; caspofungin, posaconazole will start the clinical trials in Japan. But, when we consider the background of the patients, new approaches of the treatments, such as immunological therapy or some supporting therapies, should be considered.
Niki
Yoshihito
Y
Department of Clinical Infectious Diseases, School of Medicine, Showa University.
D000935:Antifungal Agents / Q000008:administration & dosage; D000077336:Caspofungin; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000639:trends*; D054714:Echinocandins; D006801:Humans; D007564:Japan; D055666:Lipopeptides; D009181:Mycoses / Q000188:drug therapy*; D014230:Triazoles
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D014230:Triazoles; C101425:posaconazole; D000077336:Caspofungin